<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964468</url>
  </required_header>
  <id_info>
    <org_study_id>RTRC--001</org_study_id>
    <nct_id>NCT02964468</nct_id>
  </id_info>
  <brief_title>Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer</brief_title>
  <official_title>Multicenter Dose-escalation Trial of Radiotherapy in Patients With Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Investigación Clínica en Oncología Radioterapia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo de Investigación Clínica en Oncología Radioterapia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the increase of radiation dose administered in patients
      diagnosed with locally advanced rectal cancer in terms of ypRC with tolerable toxicity, using
      IMRT (concomitant boost technique).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis that arises is an improvement in the proportion of pathological complete
      responses, resulting therapeutic gain, as a result of a higher dose of radiation delivered to
      the tumor volume without incurring a higher gastrointestinal toxicity to the patient or
      surgical complications later, thanks to the use of intensity modulated radiotherapy
      (concomitant boost technique) that allows us to significantly reduce the administered dose
      organs at risk.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Pathologic evaluation of the surgical specimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal toxicity</measure>
    <time_frame>Two years</time_frame>
    <description>Gastrointestinal adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor regression grade</measure>
    <time_frame>Through study completion, an average of two years</time_frame>
    <description>Pathologic evaluation of the surgical specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Two years</time_frame>
    <description>Toxicity including anorexia, nausea, vomiting, diarrhoea, dermatitis, proctitis, urinary frequency/urgency as per common toxicity criteria V4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Three years after the study completion</time_frame>
    <description>Assessed by EORTC QLQC30 and the QLQ-CR29 questionnaries</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment with IMRT Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Intensity Modulated Radiotherapy treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with 3DCRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3DCRT treatment (sequential boost)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3DCRT treatment (sequential boost)</intervention_name>
    <description>Radiotherapy:
3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.
3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.
Chemotherapy:
According to routine clinical practice of the participating centers.</description>
    <arm_group_label>Treatment with 3DCRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dose Escalation Intensity Modulated Radiotherapy treatment</intervention_name>
    <description>Radiotherapy:
IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.
Chemotherapy:
According to routine clinical practice of the participating centers.</description>
    <arm_group_label>Treatment with IMRT Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven diagnosis of adenocarcinoma of the rectum

          -  Clinically determined to be stage T3 or T4,N0-N2, and M0 -staged by MRI or transrectal
             ultrasound of the rectum

          -  Patients who are medically operable and who have resectable adenocarcinoma of the
             rectum at least &lt;11cm from the anal verge

          -  Adequate liver/renal and haematological function.

          -  Eastern Cooperative Oncology Group (ECOG) performance 0-2

          -  Age ≥ 18 years

          -  Full blood count obtained within 2 weeks prior to registration on study, with adequate
             bone marrow function defined as follows:

               -  Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3

               -  Platelets ≥ 100,000 cells/mm3

               -  Haemoglobin ≥ 8.0 g/dl

               -  Serum creatinine within normal institutional limits

               -  Bilirubin within normal institutional limits

               -  AST and ALT &lt; 2.5 x the IULN

          -  Patient must sign study specific informed consent prior to study entry

        Exclusion Criteria:

          -  Prior systemic chemotherapy for colorectal cancer; note that prior chemotherapy for a
             different cancer is allowable.

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Any evidence of distant metastases (M1)

          -  A synchronous primary colon carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando López Campos, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramón y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asunción Hervás Morón, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramón y Cajal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando López Campos, Investigator</last_name>
    <email>flcampos@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Mostoles</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Esperanza Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castellón</name>
      <address>
        <city>Castellon</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando López Campos</last_name>
      <email>flcampos@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Fernando López Campos</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asunción Hervás Morón</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Martín Martín</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2016</study_first_submitted>
  <study_first_submitted_qc>November 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>November 12, 2016</last_update_submitted>
  <last_update_submitted_qc>November 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grupo de Investigación Clínica en Oncología Radioterapia</investigator_affiliation>
    <investigator_full_name>Asunción Hervas</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>IMRT</keyword>
  <keyword>Radiation Dose Escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

